Sign In
Buy AKRO
$54.65
+0 (+0%)
At Close: Mar 06, 2026
Akero Therapeutics poised to be leader in NASH with upcoming trial data readout potential stock catalyst
04:03pm, Monday, 28'th Aug 2023
Akero Therapeutics could become a leader in non-alcoholic steatohepatitis (NASH) treatment, according to analysts at UBS who have initiated coverage on the stock with a ‘Buy' rating. NASH is an adva
Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023
07:00am, Monday, 28'th Aug 2023
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious meta
Weight-loss drugs in development aim to replace injections with pills
03:21pm, Monday, 26'th Jun 2023
Wall Street's obsession with next-generation obesity and diabetes treatments intensified over the weekend as drugmakers presented new clinical-trial data on the drugs — including weight-loss pills i
Recent Price Trend in Akero Therapeutics, Inc. (AKRO) is Your Friend, Here's Why
10:32am, Monday, 26'th Jun 2023
Akero Therapeutics, Inc. (AKRO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
GSK Announces Extension of FDA Review for Rare Blood Therapy
11:43am, Monday, 19'th Jun 2023
GSK announces the FDA's extension of the review period of its new drug application for momelotinib to treat myelofibrosis by three months. A decision is now expected on Sep 16, 2023.
Is Akero Therapeutics (AKRO) Outperforming Other Medical Stocks This Year?
10:47am, Tuesday, 13'th Jun 2023
Here is how Akero Therapeutics, Inc. (AKRO) and Accelerate Diagnostics (AXDX) have performed compared to their sector so far this year.
3 Mid Caps You Haven't Heard Of But Need To Know About
07:00am, Friday, 09'th Jun 2023
There have been plenty of headlines in recent weeks regarding the influence a few tech titans are having on the broader market rally that's underway, with some voices suggesting the S&P 500 would actu
Akero Therapeutics, Inc. (AKRO) Is a Great Choice for 'Trend' Investors, Here's Why
10:03am, Wednesday, 07'th Jun 2023
Akero Therapeutics, Inc. (AKRO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that pass
Akero says NASH drug shown to reduce liver fat by 65% in some patients
11:02am, Monday, 05'th Jun 2023
Akero Therapeutics Inc said on Monday data from a mid-stage study showed its experimental therapy reduced liver fat by 65% in certain patients with a type of fatty liver disease called nonalcoholic st
Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1
04:05pm, Thursday, 01'st Jun 2023
Investor webcast on Monday, June 5 at 8:00 a.m. ET to present clinical data Investor webcast on Monday, June 5 at 8:00 a.m. ET to present clinical data
Akero Therapeutics to Present at the Jefferies Healthcare Conference
08:00am, Wednesday, 31'st May 2023
SAN FRANCISCO, May 31, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease m
How Much Upside is Left in Akero Therapeutics, Inc. (AKRO)? Wall Street Analysts Think 29.22%
11:08am, Tuesday, 23'rd May 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 29.2% in Akero Therapeutics, Inc. (AKRO). While the effectiveness of this highly sought-after metric is questio
Akero Therapeutics: A Promising Solution For NASH Patients And Investors
02:17am, Thursday, 18'th May 2023
Strong clinical results, including significant reductions in liver fat, improvements in glycemic control, and fibrosis regression without worsening of NASH, support the efficacy and potential of EFX.
Akero Therapeutics: Proof Of Concept With EFX, Sets Up Catalyst Opportunities In 2023
04:37am, Tuesday, 09'th May 2023
Akero Therapeutics has a proof of concept in using EFX for the treatment of patients with NASH Fibrosis established in the phase 2b HARMONY study. Results from cohort D of phase 2b SYMMETRY study usin
Akero Therapeutics: Excellent Data, Solid Clinical Potential, No Major Near Term Catalysts
10:05am, Sunday, 07'th May 2023
AKRO will produce phase 2b SYMMETRY data in 4Q, but phase 3 will be a few years away. I believe Madrigal's success and the far off phase 3 may dampen exuberance around SYMMETRY.
